BioCentury | May 25, 2018
Company News

Antengene adds bundle of Karyopharm assets to pipeline

...the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor (KPT-8602...
...on May 24. Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Newton, Mass. Antengene Corp., Shanghai, China Business: Cancer Allison Johnson KPT-8602 KPT-9274 selinexor...
BioCentury | May 24, 2018
Company News

Antengene fills pipeline with Karyopharm deal

...the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor (KPT-8602...
...last year (see BioCentury, Aug. 18, 2017) . Karyopharm slipped $1.72 to $17.34 on Thursday. Allison Johnson KPT-8602 KPT-9274 selinexor...
BioCentury | Oct 13, 2017
Company News

Ono gets rights to SINE compounds from Karyopharm

...Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights to develop and commercialize selinexor ( KPT-330 ) and KPT-8602...
...liposarcoma. Top-line data from BOSTON the Phase III portion of SEAL are expected in 2019. KPT-8602...
Items per page:
1 - 3 of 3